(Q44620749)

4 December 2017

Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia (English)

1 reference

4 December 2017

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia (English)

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

22 March 2024

0 references

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

22 March 2024

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

22 March 2024

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

22 March 2024

6

John C Byrd

1 reference

4 December 2017

2

Ian W. Flinn

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14563637

22 March 2024

author name string

Rama Modali

3

1 reference

4 December 2017

Donn Young

5

1 reference

4 December 2017

Sherif S. Farag

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14563637

22 March 2024

Teresa A. Lehman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14563637

22 March 2024

language of work or name

English

0 references

publication date

16 October 2003

1 reference

full work available at URL

4 December 2017

3

1 reference

based on heuristic

inferred from page(s)

published in

Blood

1 reference

4 December 2017

103

1 reference

4 December 2017

4

1 reference

4 December 2017

1472-1474

1 reference

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

4 December 2017

1

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

22 March 2024

2

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

Rituximab dose-escalation trial in chronic lymphocytic leukemia

22 March 2024

3

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

22 March 2024

4

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

22 March 2024

7

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

22 March 2024

9

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.

22 March 2024

10

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

22 March 2024

11

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

22 March 2024

12

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease

22 March 2024

13

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy

22 March 2024

15

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

Chronic lymphocytic leukemia

22 March 2024

16

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

22 March 2024

17

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species

22 March 2024

18

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

22 March 2024

19

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

22 March 2024

21

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma

22 March 2024

22

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.

22 March 2024

23

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-07-2548

22 March 2024

Identifiers

1 reference

4 December 2017

1 reference